CD22 deficiency influences the incidence of B cell lymphoma

被引：0
|
作者：
Inaoki, M
Sato, S
Hasegawa, M
Tedder, TF
Takehara, K
机构：
[1] Kanazawa Univ, Grad Sch Med Sci, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan
[2] Duke Univ, Ctr Med, Dept Immunol, Durham, NC 27706 USA
来源：
FASEB JOURNAL | 2003年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：C324 / C324
页数：1
相关论文
共 50 条
  • [31] Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact
    Collins, BE
    Blixt, O
    DeSieno, AR
    Bovin, N
    Marth, JD
    Paulson, JC
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (16) : 6104 - 6109
  • [32] B cell depletion therapy with cytotoxic liposomes containing glycan ligands of CD22: A novel strategy for treatment of human B cell lymphoma
    Chen, Weihsu
    Completo, Gladys
    Paulson, James
    CANCER RESEARCH, 2009, 69
  • [33] Dendritic cell-dependent inhibition of B cell proliferation requires CD22
    Santos, Lorna
    Draves, Kevin E.
    Boton, Mark
    Grewal, Prabhjit K.
    Marth, Jamey D.
    Clark, Edward A.
    JOURNAL OF IMMUNOLOGY, 2008, 180 (07): : 4561 - 4569
  • [34] CD22 deficiency alters B cell populations and plasma triglyceride levels but does not affect atherosclerosis in hyperlipidemic mice
    Porsch, F.
    Kiss, M.
    Tsiantoulas, D.
    Goederle, L.
    Ozsvar-Kozma, M.
    Binder, C. J.
    CARDIOVASCULAR RESEARCH, 2018, 114 : S96 - S96
  • [35] In vivo targeting of B-cell lymphoma with glycan ligands of CD22 (vol 115, pg 4778, 2010)
    Chen, W. C.
    Completo, G. C.
    Sigal, D. S.
    BLOOD, 2011, 117 (20) : 5551 - 5551
  • [36] Soluble CD22, a new test which correlates with disease status in B-cell leukemia and lymphoma.
    Kreitman, RJ
    Wilson, WH
    Margulies, A
    Pastan, I
    Matsushita, K
    BLOOD, 2002, 100 (11) : 757A - 757A
  • [37] Modulation of CD22 Antigen Density Improves Efficacy of CD22 Chimeric Antigen Receptor (CAR) T Cells Against CD22lo B-Lineage Leukemia and Lymphoma
    Ramakrishna, Sneha
    Nguyen, Sang M.
    Qin, Haiying
    Highfill, Steven L.
    Kraft, Ira
    Shern, John
    Walsh, Zachary
    Dimitrov, Dimiter
    Fry, Terry J.
    BLOOD, 2017, 130
  • [38] Manipulation of CD22 signal transduction for the treatment of lymphoma.
    Tuscano, JM
    DeNardo, G
    Wun, T
    Tedder, TF
    Kehrl, JH
    BLOOD, 1999, 94 (10) : 93A - 93A
  • [39] Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies
    O'Keefe, TL
    Williams, GT
    Batista, FD
    Neuberger, MS
    JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (08): : 1307 - 1313
  • [40] Analysis of tyrosine phosphorylation sites of CD22 upon B cell activation
    Fujimoto, M
    Yoshitake, S
    Tedder, TF
    Takehara, K
    FASEB JOURNAL, 2005, 19 (04): : A953 - A953
12345